HTG Molecular Diagnostics and Oncologie, Inc. Complete Master Agreement to Partner on Biomarker Development for Immuno-oncology Drug Development

Press Release | ASource: HTG Molecular Diagnostics, Inc.

TUCSON, Ariz., Aug. 03, 2018 (GLOBE NEWSWIRE) — HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a provider of instruments, reagents, and services for molecular profiling applications and Oncologie, Inc. an innovative biotechnology company with operations in Boston and Shanghai, today announced the completion of a master agreement where the companies have agreed to partner on the development of biomarkers associated with Oncologie’s Immuno-oncology pipeline.

“We are honored to be working with Oncologie on biomarker development programs for their innovative pipeline of Immuno-oncology assets,” stated TJ Johnson HTG Chief Executive Officer. “HTG is committed to the development of NGS-based precision diagnostics to support biomarker driven drug development, and we share a common focus with Oncologie in the field of Immuno-oncology.”

Laura Benjamin Ph.D., Oncologie Chief Executive Officer and founder added, “We believe HTG’s technology and assay development capabilities will assist our clinical development efforts as we strive to bring innovative new medicines to cancer patients globally.”

About Oncologie, Inc.

ONCOLOGIE is an oncology therapeutics company committed to delivering better outcomes for cancer patients through an improved understanding of which patients will benefit from each drug in the pipeline. The current pipeline is focused on mid-stage clinical programs that modify the immune system to enhance efficacy of current standards of care and emerging immunotherapy agents. Headquartered in Boston, Massachusetts and Shanghai, China, Oncologie is working with global partners to acquire and develop innovative drugs for cancer patients around the world.

About HTG:

HTG is focused on next generation sequencing (NGS) based molecular profiling. The company’s proprietary HTG EdgeSeq technology automates complex, highly multiplexed molecular profiling from solid and liquid samples, even when limited in amount. HTG’s customers use its technology to identify biomarkers important for precision medicine, to understand the clinical relevance of these discoveries, and ultimately to identify treatment options. Our mission is to empower precision medicine at the local level.